Clinical Trial Update: ImPrEP LEN Brasil: Twice-Yearly Lenacapavir for HIV Prevention [NA]

View source ↗

Summary

An ongoing Brazilian HIV prevention trial (ImPrEP LEN Brasil) is evaluating twice-yearly lenacapavir for people at risk of HIV exposure, with recruitment curren…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• HIV Infection

Drugs mentioned

• Lenacapavir (lenacapavir)

Snippet

Sponsor: Oswaldo Cruz Foundation | Conditions: Contact With or Exposure to Human Immunodeficiency Virus | NA | Status: RECRUITING